Abstract
Introduction
T cell immunosurveillance can prevent the development of several malignancies.
Nevertheless, the common occurrence of neoplasia shows that cancer immunosurveillance is leaky. Not only are cancer cells commonly ignored by the immune system, but they can also induce anergy or deletion of tumor-reactive T cells.
And, it has proven exceedingly difficult to elicit curative immune responses with tumor vaccines. 1, 2 Several factors explain the disappointing results obtained in tumor vaccine trials: low immunogenicity of tumor associated epitopes, absence of high-avidity tumorreactive T cells in the peripheral T cell repertoire, location of cancer cells outside the secondary lymphoid organs, and microenvironmental features in the tumor cell stroma (physical barriers, cytokines) that hinder productive interactions between T cells and cancer cells. [3] [4] [5] [6] [7] Many drawbacks of tumor vaccines can be curtailed by the use of adoptive T cell immunotherapy. 8 Indeed, the T cell repertoire from an allogeneic donor comprises T lymphocytes that can recognize with high avidity non self epitopes expressed by recipient cancer cells. Furthermore, these T cells can be primed ex vivo against their target antigen prior to adoptive transfer. Injected cells can either be self MHC-restricted T lymphocytes that recognize polymorphic MHC-associated peptides, that is, minor histocompatibility antigens (MiHA), or be allo MHC-restricted. [9] [10] [11] [12] [13] Many clinical studies have shown that a single injection of allogeneic lymphocytes can eradicate up to 10 12 hematopoietic malignant cells. [14] [15] [16] [17] The remarkable efficacy of adoptive T cell immunotherapy in
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From eradicating leukemia/lymphoma cells probably constitutes the most convincing evidence that T lymphocytes can cure established cancer. 15 Moreover, recent studies suggest that the efficacy of adoptive immunotherapy can be extended to the treatment of solid tumors. 18, 19 The use of this approach however, has been limited by the fact that (Fig. 1 A) and that the proportion of cells with this phenotype in the BM, lymph nodes and spleen of normal mice was 0.02% ( Fig. 1 B) . In this and all further experiments pre-immunization was performed by intraperitoneal injection of 2 x 10 7 B10 splenocytes on day -14. Previous studies have shown that following intravenous injection of 5 x 10 5 EL4 cells, the cancer death rate in naïve B10, naïve B10.H7 b and pre-immunized B10.H7 b mice, was 100%, 80% and 0%, respectively.
Expansion kinetics of B6 dom1 -specific T cells and EL4 cells following intravenous injection of EL4 cells into naïve and pre-immunized mice
The median time to death was day 25 for B10 mice and day 36 for naive B10.H7 b mice. 20 After day 10, EL4 expanded rapidly and at similar pace in the BM, lymph nodes and spleen of B10 mice (Fig. 2 A) We estimated the number of B6 dom1 -specific CD8 T cells at the same time points in naïve and pre-immunized B10.H7 b mice challenged with EL4 cells (Fig. 2 B) . In addition, a control group of pre-immunized mice was re-injected with B10 cells to evaluate whether the type of cells used for challenge, neoplastic or not, influenced the T cell response. In naïve B10.H7 b mice injected with EL4 cells, numbers of B6 dom1 -specific T cells increased slowly in the spleen and lymph nodes during the first ten days, then remained relatively unchanged to day 25. This kinetics of expansion of antigen specific CD8 T cells in naive mice was unlike the brisk expansion followed by a rapid decline after days 5 to 10 typically seen during the course of acute viral and bacterial infections. 25 Expansion of B6 dom1 -specific T cells was more rapid and extensive in pre-immunized than in naive mice. Interestingly, its duration was considerably prolonged when the cells injected on day 0 were EL4 as opposed to B10 cells. The latter point indicates that elimination of rapidly proliferating neoplastic cells is more demanding for the immune system than elimination of normal cells. 3 A) was different from that observed in untransplanted mice (Fig. 2 A) . injected with EL4 cells, the number of B6 dom1 -specific T cells in the spleen reached a peak of ~120 x 10 3 on day 15 and decreased progressively thereafter (Fig. 3 B) . This was significantly (P < 0.05), though not exceedingly superior to the levels observed in We next assessed by Annexin V staining the rate of apoptosis since it determines, in conjunction with the mitotic rate, the kinetics of T cell accumulation. At all time points, the proportion of apoptotic B6 dom1 tetramer + T cells showed dramatic increase in B10 compared with B10.H7 b hosts (Fig. 4 A) confronted with a highly abundant epitope. 25 In accordance with this, mean fluorescence intensity of B6 dom1 tetramer labeling was remarkably decreased in B10 relative to B10.H7 b hosts ( Fig. 4 B) ; this was true for both Annexin V-positive and -negative tetramer + T cells (Fig. 4 C) .
Antigen driven T cell expansion is not synonymous with protective immunity.
Accumulating evidence indicates that antigen specific CD8 T cells may expand considerably in vivo yet show defective effector activity [reviewed in 26 ] . We therefore compared the cytotoxic activity of freshly harvested CD8 T cells from B10 and B10.H7 b recipients. On day 15, CD8 splenocytes were directly assayed for cytotoxic activity ( 3 Hthymidine release) against EL4 cells (Fig. 4 D) . The nature of the host had a dramatic influence on anti-EL4 effector function: strong cytotoxicity was observed with CD8 T cells from B10.H7 b but not from B10 hosts (P = 0.02).
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Discussion
The crucial point emerging from this work is that the tissue distribution of target antigen, here B6 dom1 , has a profound influence on the outcome of adoptive T cell immunotherapy.
When B6 dom1 -primed T cells were injected in recipients (B10.H7 b ) in which B6 dom1 was present only on EL4 cancer cells, B6 dom1 -specific T cells expanded to reach a peak in host spleen on day 15 and progressively declined thereafter, displayed direct cytotoxic activity, and completely eliminated EL4 cells. In contrast, when B6 dom1 was ubiquitously expressed (B10 hosts), B6 dom1 -specific T cells proliferated more extensively but showed poor effector function, underwent major AICD, and were less effective at eradicating EL4 cells. These data explain why the EL4 cure rate is 100% in B10.H7 b but only 60% in B10 hosts. 20 Moreover, this correlation between antigen load and the fate of injected T cells is strikingly similar to what is observed with T cell response to the lymphocytic choriomeningitis virus. 25 Thus, the risk of AICD following adoptive immunotherapy must be taken into account whether the target antigen is a viral epitope or an endogenous host MHC class I-associated peptide (the immunodominant B6 dom1 MiHA in our model).
As a corollary, our finding that overstimulated donor-derived T cells can become dysfunctional implies that assessing the level of protection afforded by adoptive cancer immunotherapy will probably require combined phenotypic and functional analyses of antigen specific T cells.
Our data demonstrate that in cancer treatment, the pitfalls inherent to adoptive immunotherapy differ from those associated with vaccination. Thus, following
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From vaccination with tumor associated antigens the strength of the immune response increases in parallel with antigen dose and AICD is not an issue. 27 Because tumor associated antigens elicit mainly low-avidity T cells, the efficacy of tumor vaccines is limited by poor immunogenicity rather than AICD. The notion that AICD is a possible outcome adoptive cancer immunotherapy has several implications. Thus, the fact that alloreactive T cells can become hyporesponsive and disappear subsequent to AICD would explain a well recognized paradox: malignancies relapsing post-AHCT remain sensitive to donor anti -h ost CTLs in vitro, and can be successfully treated with re-injection of lymphocytes from the original donor. 14, 17, 28 Based on our work, we speculate that most leukemic relapses are due to the disappearance of effector/memory T cells rather than to the emergence of resistant neoplastic cells. For how long must adoptively transferred T cells persist to achieve cancer cure has yet to be determined. 28, 29 Nevertheless, since some cancers relapse months to years post-AHCT, continuous remission may require long-term persistence of memory T cells. Further studies will be required to assess the expression profile of immunodominant human MiHAs and to what extent these antigens can induce AICD of adoptively transferred T cells. In any case, one inference from the present work is that when adoptive immunotherapy is targeted to an abundant and widely expressed antigen, strategies will need to be developed to prolong the survival of donor T cells. In further studies we intend to evaluate whether this might be achieved by increasing supply of cytokines such as IL-7 or IL-15. [30] [31] [32] [33] When possible, it may be preferable to target epitopes with a limited tissue distribution.
For First, when T cells primed in secondary lymphoid organs accumulate in other organs simply because of random dissemination, the kinetics of T cell accumulation and disappearance is similar in lymphoid and non-lymphoid organs. 36, 37 This was clearly not the case here: accumulation of B6 dom1 -specific T cells in the BM started later but lasted much longer than in the spleen (Fig. 3 B) . Secondly and of special significance, although B6 dom1 is expressed by hematopoietic and non-hematopoietic cells of all tissues and organs of B10 mice, 20, 21 only when these recipients were injected with EL4 cells did B6 dom1 -specific T cells accumulate in the BM (Fig. 3 B) . This is notably different from what was seen in the spleen where the expansion of B6 dom1 -specific T cells was influenced more by the presence of B6 dom1 on normal host cells than by the presence or absence of EL4 cells. These data strongly suggest that T cells expanded in the BM because EL4 cells, which accumulated chiefly there, induced in situ proliferation of B6 dom1 -specific T cells that had migrated to the BM.
In the BM of transplanted leukemic mice, the number of B6 dom1 -specific T cells increased over the entire observation period (35 days) without any evidence of attrition.
This suggests that following adoptive immunotherapy, the main sites of tumor growth (rather than the classical secondary lymphoid organs) are the main repositories of effector/memory T cells. It will be important to solve the cause behind this finding.
Indeed, assuming its generality, this paradigm would imply that local monitoring of the immune response at the site of tumor growth may be mandatory for a meaningful assessment of the efficacy of adoptive immunotherapy. 
